runx3、chfr基因启动子区甲基化与胃癌临床特征和预后的研究-study on methylation in promoter region of runx 3 and chfr gene and clinical characteristics and prognosis of gastric cancer.docxVIP

下载本文档

3
0
约4.12万字
约 53页
2018-06-03 发布于上海
举报
版权申诉

runx3、chfr基因启动子区甲基化与胃癌临床特征和预后的研究-study on methylation in promoter region of runx 3 and chfr gene and clinical characteristics and prognosis of gastric cancer.docx

1、本文档共53页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

runx3、chfr基因启动子区甲基化与胃癌临床特征和预后的研究-study on methylation in promoter region of runx 3 and chfr gene and clinical characteristics and prognosis of gastric cancer

安徽医科大学硕士学位论文安徽医科大学硕士学位论文 PAGE PAGE 6 Results In gastric cancer tissues, the methylation frequencies of RUNX3 and CHFR genes were found to be 54.4% and 41.4% respectively, while in benign gastric mucosae, they were both found to be 0, the methylation frequencies of the two genes in cancer tissues were significantly higher than that in benign gastric mucosae (P＜0.05). The methylation frequencies of RUNX3 and CHFR genes were found to be 62.7% and 49.3% in cancer tissues with tumor size ≥5cm, and in cancer tissues with tumor size ＜5cm, they were 41.7% and 29.2%, respectively. The frequencies of RUNX3 and CHFR methylation in tumor size ≥5cm were significantly higher than those in tumor size ＜5cm (PRUNX3 = 0.023, PCHFR = 0.027). In cancer tissues with stage T3/T4 and T1/T2, the frequencies of RUNX3 methylation were 62.2% and 33.3% respectively, the former was significantly higher than the latter. In cancer tissues with stage G3/G4 and G1/G2, the methylation frequencies of CHFR were 50.0% and 25.6% respectively, the former was significantly higher than the latter. No significant relationship was found between RUNX3 and CHFR methylation and other clinicopathological features including the age, gender, stage of pathology and the involvement of lymph node (P＞0.05). The survival duration after surgical resections in patients with methylated CHFR was significantly shorter than that in patients with unmethylated CHFR (PCHFR = 0.03), while no significantly result was found between RUNX3 methylation status and survival duration after surgical resections in gastric cancer patients (P = 0.27). The median survival time of gastric cancer patients with tumor size ＜ 5cm was significantly longer than those with tumor size ≥5cm (P=0.04). There were no significant associations between other factors such as age, sex, tumor differentiation, the involvement of lymph node, stage of pathology and tumor invasion depth and the median survival time of gastric cancer patients. Conclusions Aber